The BTK inhibitor ibrutinib has shown significant efficacy in relapsed/refractory ABC-DLBCL patients, especially in those tumors with concurrent MYD88L265P and CD79B mutations (97). This evidence concerns the gene CD79B and diffuse large B-cell lymphoma.